The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

AstraZeneca PLC closed 14.73% below its 52-week high of £133.88, which the company achieved on September 3rd.

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel ...

Bullish option flow detected in AstraZeneca (AZN) with 7,924 calls trading, 1.2x expected, and implied vol increasing almost 3 points to 23.67%. Apr-25 73 calls and Apr-25 75 calls are the most ...

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

[HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual ...

AstraZeneca is a company with a turbulent history ... It is based on an adenoviral vector based on a weakened version of the adenovirus that causes a common cold-line illness in chimpanzees ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...